<DOC>
	<DOC>NCT00195208</DOC>
	<brief_summary>The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.</brief_summary>
	<brief_title>Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>GERD and a history of Erosive Esophagitis documented by endoscopy H. pylori negative Gastrointestinal conditions such as esophageal stricture, esophageal varices, previous vagotomy Achlorhydria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Gastroesophageal Reflux Disease (GERD)</keyword>
</DOC>